(Q33574857)

28 July 2017

title

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience (English)

1 reference

28 July 2017

1 reference

Satoshi Yamada

1

1 reference

28 July 2017

Takuya Yoshino

2

1 reference

28 July 2017

Minoru Matsuura

3

1 reference

28 July 2017

Naoki Minami

4

1 reference

28 July 2017

Takahiko Toyonaga

5

1 reference

28 July 2017

Yusuke Honzawa

6

1 reference

28 July 2017

Yoshihisa Tsuji

7

1 reference

28 July 2017

Hiroshi Nakase

8

1 reference

28 July 2017

language of work or name

1 reference

23 April 2014

1 reference

28 July 2017

1 reference

28 July 2017

volume

14

1 reference

28 July 2017

page(s)

80

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-230x-14-80

28 July 2017

exact match

0 references

cites work

Establishment of a novel mouse model of ulcerative colitis with concomitant cytomegalovirus infection: in vivo identification of cytomegalovirus persistent infected cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

Management of cytomegalovirus infection in inflammatory bowel diseases.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

Mucosal healing in inflammatory bowel disease-a true paradigm of success?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

Optimal use of biologics in the management of Crohn's disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

Infliximab for induction and maintenance therapy for ulcerative colitis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

Optimizing anti-TNF treatment in inflammatory bowel disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4012244

Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis.

14 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-14-80

Phenotypic features of Crohn's disease associated with failure of medical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-14-80

A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-14-80

Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-14-80

Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-14-80

Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-14-80

Long-term outcome after infliximab for refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-14-80

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-14-80

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis

21 January 2018

1 reference

12 December 2020

Infliximab dose intensification in Crohn's disease

1 reference

12 December 2020

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism

1 reference

12 December 2020

Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy

1 reference

12 December 2020

Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up

1 reference

12 December 2020

Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies

1 reference

12 December 2020

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

1 reference

12 December 2020

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

1 reference

12 December 2020

Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-230X-14-80

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference